Le Lézard5d
U.S. FDA Accepts Gilead's New Drug Applications for Twice-Yearly Lenacapavir for HIV Prevention Under Priority Review
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir?the company's twice-yearly injectable HIV ...
Allurion Technologies to initiate Allurion Balloon with GLP-1 agonists study
Allurion Technologies (ALUR) announced its intention to initiate a clinical study on the combination of the Allurion Balloon with GLP-1 ...
Yahoo Finance5d
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less TM ...
Business Wire4d
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
About Allurion Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable ...
TMCnet3d
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
In addition, the Company closed its previously announced concurrent private placement with funds affiliated with Leavitt Equity Partners for the purchase and sale of 267,686 shares of common stock and ...
Business Wire3d
Allurion Announces Closing of Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
About Allurion Allurion is dedicated to ending obesity. The Allurion Program is a weight-loss platform that combines the Allurion Gastric Balloon, the world’s first and only swallowable ...